**Registry WG(PD1)/N46**



**Proposed Document**

**International Medical Device Regulators Forum**

**Title:** Tools for Assessing the Usability of Registries in Support of Regulatory



Decision-Making

**Authoring Group:** Patient Registries Working Group

**Date:** 17August 2017

**Table of Contents**

[1.0 Introduction 4](#_Toc490833090)

[2.0 Scope 4](#_Toc490833091)

[3.0 References 5](#_Toc490833092)

[4.0 Definitions 7](#_Toc490833093)

[5.0 Elements for Assessment of Registry for Regulatory Uses 8](#_Toc490833094)

[5.1 Device Identification 8](#_Toc490833095)

[5.2 Linkability 10](#_Toc490833096)

[5.2.1 Deterministic (direct) 10](#_Toc490833097)

[5.2.2. Probabilistic (indirect) 10](#_Toc490833098)

[5.3. Transparency and Governance 11](#_Toc490833099)

[5.3.1. Governance Structure and Processes 11](#_Toc490833100)

[5.3.2. Legal and Ethical Requirements for Data Collection and Handling 11](#_Toc490833101)

[5.3.3. Policy on Conflict of Interest 12](#_Toc490833102)

[5.3.4. Policy on Access to Data 12](#_Toc490833103)

[5.3.5. Reports - Key Elements, Frequency and Web- reporting 12](#_Toc490833104)

[5.3.6. Essential Information Available for Verification by Relevant Authority 13](#_Toc490833105)

[5.3.7. Information on Patient Data Protection and Data Security 13](#_Toc490833106)

[5.4. Quality and Methodology Processes Leading to Actionable Data 14](#_Toc490833107)

[5.4.1. Relevant Variables and Use of Controlled Vocabularies 14](#_Toc490833108)

[5.4.2. Use of nationally/internationally harmonized data models 14](#_Toc490833109)

[5.4.3. Registry Data Management and Quality Management Programs 14](#_Toc490833110)

[5. 4. 4. Conduct of Analyses across Different Types of Analysis Framework 15](#_Toc490833111)


[6. APPENDIX 1: Proposed Assessment Check List by Regulatory Use 16](#_Toc490833112)

#### Preface

The document herein was produced by the International Medical Device Regulators Forum (IMDRF), a voluntary group of medical device regulators and experts from other sectors of the medical device ecosystem from around the world. The document has been subject to consultation throughout its development.

There are no restrictions on the reproduction, distribution or use of this document; however, incorporation of this document, in part or in whole, into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

# Introduction

Registries (including registry consortia and strategically coordinated registry networks (CRNs)) are critical data infrastructure for capturing outcomes associated with medical device use, and as such continue to demonstrate an impact on the quality of clinical care worldwide. In 2014 the International Medical Device Regulators Forum (IMDRF) identified a significant gap in optimal use of registries for regulatory decision making. This led to the creation of IMDRF Registry Working Group that produced two documents to guide alignment and use of registries generated data with regulatory decision making needs; (1) Principles of International System of Registries Linked to Other Data Sources and Tools, (2) Methodological Principles in the Use of International Medical Device Registry Data.

In the **first document** the registry system was defined

and eight registry qualifiers were identified to enhance its impact and sustainability (Figure 1). In the **second document** regulatory perspectives for registry quality and data use were identified and optimal methodologies for analysis of heterogeneous data sources were introduced.

**Figure 1.** IMDRF Context: Relationship

Between the Registry Documents

# Scope

The purpose of this **third document** is to provide advice to regulators of medical devices and registry organizations on the use of registry-generated data in support of regulatory decisions. Such decisions include (a) primary device approval, (b) expanded/broadened indications, (c) post-market studies, (d) post-market surveillance, (e) development of objective performance criteria (OPCs)/performance goals (PGs) and (f) device tracking/ field safety correction actions.

This document identifies key processes and features to be considered in assessing the usability of registry data for regulatory purposes, encompassing both (a) data produced by registries and (b) data produced by linkability to other sources (including other registries) to enrich the evidence available for regulatory decision-making. These assessment elements are intended to apply to both (a) purpose-built medical device registries (including those sponsored by manufacturers) and (b) other types of patient registries (e.g. quality registries), such as those that assemble data on surgical procedures that have a potential to generate data about medical devices.

The authors of this document recognize that data produced by a registry may be suitable for making one type of regulatory decision but not others. Individual country regulators are expected to both (a) assess independently the suitability of registry-generated data for regulatory purposes and (b) decide what actions to take based on applicable national and regional regulations. The assessment elements identified in this document do not constitute a checklist of requirements to certify registry organizations or to assign numerical quality ratings to registry-produced data. If, based on use of the assessment elements contained in this document, regulators find that checklist may be useful, additional work will be required to produce a robust assessment tool.

This document is intended (a) to promote convergence of regulatory approaches, (b) to enhance the technical capabilities of medical device regulators and other ecosystem stakeholders, and (c) to accelerate evidence generation. It may be useful to registry organizations that want their data to be considered in regulatory decision-making. The stakeholders are encouraged to compare elements discussed in this document to their current processes and consider closing any evidence gaps that are found. This document may also be helpful to manufacturers of medical devices that want to include registry-generated data in their regulatory applications. In summary, the use of the assessment elements described in this document is expected to promote consistency, predictability, and transparency in maximizing the utility of real-world data in the evaluation of (a) medical device safety, effectiveness, and reliability and (b) patients' acceptance of and satisfaction with medical devices.

The proposed assessment checklist in the Appendix 1 is intended to provide recommendations of the acceptable levels of key registry attributes/elements for various regulatory uses (e.g. XX representing the most stringent requirements/expectations).

# References

1. A Report from the Medical Device Registry Task Force & the Medical Devices Epidemiology Network. Recommendations for a National Medical Device Evaluation System. Strategically Coordinated Registry Networks to Bridge Clinical Care and Research, August 2015. Available at: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/cdrhreports/ucm459368.pdf. Accessed August 10, 2017;
2. Australian Government, National Statistical Service, Data Linking. Available at:

<http://www.nss.gov.au/nss/home.nsf/533222ebfd5ac03aca25711000044c9e/91242a5a14b12e26ca257ba8007b0819/$FILE/probabilistic%20datalink%204p%20w.pdf>) Accessed August 10, 2017;

1. Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval; Available at: (<http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm393994.pdf>); Accessed August 10, 2017;
2. CITI Recommendations: Registry Trials: Accessed (<https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/registrytrials-recs.pdf>); Accessed August 10, 2017;
3. Dusetzina SB, Tyree S, Meyer AM, et al. Linking Data for Health Services Research: A Framework and Instructional Guide [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Sep. 4, An Overview of Record Linkage Methods. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK253312/>); Accessed August 10, 2017;
4. Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications; Available at: (<http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm517504.pdf>); Accessed August 10, 2017;
5. Final Report PARENT Joint Action (2015); Available at:   
   ([http://ec.europa.eu/health/ehealth/docs/ev\_20151123\_co05\_en.pdfhttp://ec.europa.eu/health/ehealth/docs/ev\_20151123\_co05\_en.pdf](http://ec.europa.eu/health/ehealth/docs/ev_20151123_co05_en.pdf) ); Accessed August 10, 2017;
6. Jaro MA. Probabilistic linkage of large public health data files. *Stat Med* 1995; 14(5-7): 491-8).
7. MEDDEV 2.7.1. rev. 4 (EU)
8. Methodological Principles in the Use of International Medical Device Registry Data, IMDRF/Registry WG/N42FINAAL: 2017
9. Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring (PCORI Conduct of Registry Studies; (<http://www.pcori.org/sites/default/files/Standards-in-the-Conduct-of-Registry-Studies-for-Patient-Centered-Outcomes-Research1.pdf>); Accessed August 6, 2017
10. Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling (Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling; Available at: <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf>); Accessed August 10, 2017;
11. PCORI Conduct of Registry Studies; Available at: (<http://www.pcori.org/sites/default/files/Standards-in-the-Conduct-of-Registry-Studies-for-Patient-Centered-Outcomes-Research1.pdf>); Accessed August 10, 2017;
12. Principles of International System of Registries Linked to Other Data Sources and Tools, IMDRF/Registry WG/N33FINAL: 2016;
13. Recommendations for a National Medical Device Evaluation System: Strategically Coordinated Registry Networks to Bridge the Clinical Care and Research - August 2015; Available at: (<http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM459368.pdf>); Accessed August 10, 2017
14. Registry-Based Prospective, Active Surveillance of Medical-Device Safety
15. Registry Assessment of Peripheral Interventional Devices (RAPID) J. Pablo Morales, Robert J. Thatcher, MBA; Jack L. Cronenwett. Retrived from: <http://evtoday.com/pdfs/et0816_RU_FDA.pdf>. Accessed August 10, 2017;
16. REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EECEU MDR;
17. REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation);
18. Sedrakyan, A., Paxton, E. W., & Marinac-Dabic, D. Stages and Tools for

Multinational Collaboration: The Perspective from the Coordinating Center of the

International Consortium of Orthopaedic Registries (ICOR).” *The Journal Of Bone & Joint*

*Surgery*, 93(Supplement 3), 76-80. (2011): DOI: 10.2106/Jbjs.K.01141

1. Sedrakyan, A., Marinac-Dabic, D., Holmes, D. R., & Jr. “The International Registry Infrastructure for Cardiovascular Device Evaluation and Surveillance.” *JAMA*, 310(3), 257- 259. (2013): DOI: 10.1001/jama.2013.7133
2. Strengthening Our National System for Medical Device Postmarket Surveillance; Available at:(<http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM301924.pdf>); Accessed August 10, 2017;
3. Strengthening Our National System for Medical Device Postmarket Surveillance: Update and Next Steps - April 2013; Available at: (<http://www.fda.gov/downloads/MedicalDevices/Safety/CDRHPostmarketSurveillance/UCM348845.pdf>); Accessed August 10, 2017;
4. Strengthening Patient Care: Building a National Postmarket Medical Device Surveillance System, Available at: (<http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM435112.pdf>). Accessed August 10, 2017;
5. Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI). Draft Guidance for Industry and Food and Drug Administration Staff; Available at: (<https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM512648.pdf>); Accessed August 10, 2017;
6. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (US FDA CDRH Draft Guidance; 2016);

# Definitions

***Clinical Evaluation:*** The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (GHTF/SG5/N1:2007).

***Lifecycle:*** All phases in the life of a medical device, from the initial conception to final decommissioning and disposal (ISO 14971:2007).

***Medical Device Registry:*** An organized system that continuously and consistently collects relevant data in conjunction with routine clinical care, evaluates meaningful outcomes, and comprehensively covers the population defined by exposure to particular device(s) at a reasonably generalizable scale (e.g. international, national, regional, and health system) with a primary aim to improve the quality of patient care (Principles of International System of Registries Linked to Other Data Sources and Tools, IMDRF/Registry WG/N33FINAL: 2016;

***Signal detection:*** The process of determining patterns of association or unexpected occurrences that have the potential to impact patient management decisions and/or alter the known benefit-risk profile of a device (Methodological Principles in the Use of International Medical Device Registry Data, IMDRF/Registry WG/N42FINAAL: 2017).

# Elements for Assessment of Registry for Regulatory Uses

There are multiple and often mutually exclusive domains of registries that contribute to their suitability for regulatory decision making including (a) registry organization (that owns or controls the system), (b) registry data management system (the mechanisms that collects and processes data), (c) registry data quality program and registry outputs (e.g. data available to send to regulators). It is possible that specific registry organization will have processes aligned with elements of suggested governance, but the data generated by registry will not be relevant for specific regulatory decision.

The sections of this document touch upon all the above domains and discuss their impact on registry’s fitness for purpose. The registry assessment tool makes recommendations with regard to the six regulatory uses as follows:

1. *Primary approval* (when applicable)
2. *Expanded/Broadened indication*
3. *Post-market study*
4. *Post-market surveillance*
5. *Objective Performance Criteria/ Performance Goals - OPCs/PGs*
6. *Device tracking and field safety corrective actions*

These six regulatory uses have different requirements in terms of robustness of registry processes. For example, using registry data to obtained approval of primary indication for the device might require accurate and reliable patient data capture, using robust study designs, at clinically relevant time intervals throughout the appropriate portions of the device lifecycle, and data should be analyzed with appropriate statistical methods for addressing the pertinent scientific questions relevant for the decision making. On the other hand, registry-generated data not meeting requirements for primary indication might be able to support broadening the indications for use of already approved devices. Further, registry data may serve as a postmarket control suitable for providing ongoing information for safety surveillance and for effectiveness.

In general, levels of evidence needed to support the regulatory decisions in each use range from most robust evidence for primary indications to a less stringent when used to support device surveillance efforts.

The assessment elements described in this document for usability of registries for regulatory decision making builds on the composite of key registry attributes and recommendations identified in the previous IMDRF registry principle documents. These include (a) Device information; (b) Quality and methodological processes leading to actionable data; (c) Transparency/ Governance, and (d) Linkability to other data sources.

## Device Identification

Being able to unambiguously identify the device(s) associated with each registry record is crucial if outputs from the analysis of registry data are to be used to underpin regulatory decision. The IMDRF guidance on “Principles of International System of Registries Linked to Other Data Sources and Tools” (IMDRF/REGISTRY WG/N33FINAL:2016 – 30 September 2016) identifies eight qualifiers which define the impact, value, and sustainability of the medical device registry. The first of these relates to device identifiers and states that:

*The registry contains sufficient information to uniquely identify the device. Ideally, the unique device identifier would be included, but when the UDI is not available, the registry would include a combination of identifiers (catalogue number, manufacturer, and description) that, in combination, will assist in uniquely identifying the device.*

The most effective way to achieve unambiguous device identification is to use a recognized Unique Device Identification (UDI) system; international guidance on UDI systems is given in the IMDRF UDI guidance (IMDRF/WG/N7FINAL:2013 UDI Guidance - 9 December 2013).

UDI systems based on the IMDRF guidance have been introduced on a regional basis in recent years, for example in the US (21 CFR Parts 16, 801, 803, et al - Unique Device Identification System; Final Rule - 24 September 2013) and Europe (Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 Article 27). Systems such as these (if available) should be used by registries as the primary device identification.

For each procedure, registries should systematically record:

* Device identifiers (UDI-DI) e.g. GS1 GTIN (Global Trade Item Number) or HIBC-LIC (Labeler Identification Code) or ISBT 128-PPIC (Processor Product Identification Code)
* Production identifiers (UDI-PI) e.g. device serial number or batch/lot number

Ideally the collection of this information should be embedded in the health care delivery system so that data collection occurs as part of care delivery and is integrated with work flow of the clinical teams involved in the delivery of care. This can be achieved by scanning the barcodes on the device labels into the hospital electronic record systems at the point and time of use for onward (semi-automated) transmission to the registry. Adopting such an approach optimises data recording efficiency and accuracy, and should lead to more complete and reliable registry records.

Where UDI is not available a combination of identifiers should be adopted to unambiguously identify devices. These may include the following:

* Manufacturer
* Medical Device Name (Brand/Trade/Proprietary or Common name)
* Model
* Device catalogue / reference code (REF)
* Device serial number (preferred, if applicable)
* Device batch or lot number

For definitions of the above terms see: IMDRF/RPS WG/N19 FINAL: 2016 – 24 March 2016.

## Linkability

Most procedural or device registries have limited follow up data on outcome events but often have rich clinical information about the patients and procedures. Linkage of these registries with other, complementary data sources (e.g. subsequent health care encounters, short term complications, long-term outcomes) would yield enriched data source for regulatory purposes. In addition, linkage is often used for validation processes of registries. Complementary data may include but are not limited to other registries, national death records, electronic medical records, or longitudinal administrative claims/discharge databases. Linkability degree might depend on the rules stated by the national legal context.

There are two broad methods of data linkage:

### Deterministic (direct)

Deterministic linkage algorithms aim to determine if record pairs agree or disagree on available set of identifiers and when agreement on a given identifier is assessed as a distinct “all-or-nothing” outcome (Dusetzina SB, Tyree S, Meyer AM, et al. Linking Data for Health Services Research: A Framework and Instructional Guide).

### **5.2.2 Probabilistic (indirect**)

Probabilistic approaches to link large datasets aim to use limited identifiers applied methodologically in a way that maximizes the probability that a data field agrees given a record pair matches, minimizes the probability that a data field agrees given a record pair is unmatched, and provides greater precision from non-uniformly distributed fields (Jaro MA. Probabilistic linkage of large public health data files). It is a method that enables the combination of record information in different data sets to form a new linked dataset. It has been described as a process that attempts to link records into different files that are most likely to belong to the same person / organization. The probabilistic link uses several identifiers, in combination, to identify and evaluate links. Probabilistic binding is usually used when a unique identifier is no available or is of insufficient quality (Australian Government, National Statistical Service, Data Linking).

Also of note is that the UDI can help with probabilistic matching, but by itself does not accomplish deterministic matching unless the device is serialized.

In assessment of the usability of a registry for regulatory uses we assume that deterministic linkage is possible and is applied because direct identifiers (patient names and exact birth date, or unique health system identifier) are available in both registry and in the linkable database, and the data on these identifiers is of good quality. The probabilistic method is applied when direct identifiers are unavailable or identifiers are not reliable.

Both matching approaches have their strengths and their limitations. It is generally recommended to evaluate the probability of successful matching as a rule, and then employ a combination of deterministic and probabilistic methods that optimizes the combination of completeness of the population and accuracy of matching.

## Transparency and Governance

It is now widely recognized that transparency is an increasingly important aspect of healthcare provision and management. See for example the introduction to the European Medical Device Regulations) which includes the following (Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 recital 45):

*Transparency and adequate access to information, appropriately presented for the intended user, are essential in the public interest, to protect public health, to empower patients and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system.*

Registry transparency and governance reflect a wide variety of real world situations. Selected considerations of direct relevance to the document's purposes are discussed here and only in relevant details.

The need for appropriate transparency in all aspects of registry activities should be taken into account by those maintaining the registries. Transparency is enhanced through the establishment and continuously maintenance of a publicly accessible website that: (a) describes the aims of the registry; (b) includes key information about governance processes; (c) explains how to participate in the registry; and (d) discloses how the registry is funded. The need for transparency should be balanced by the need to maintain confidentiality with regard to identifiable information about patients, clinicians and devices.

### Governance Structure and Processes

It is important that device registries should have proper governance structures in place in order to ensure that each registry conducts/carries out its activities in an appropriate manner, particularly with regard to the handling of information about patients, clinicians, healthcare institutions and manufacturers. This can be achieved by the registry establishing a governance group (steering committee / board) which sets registry objectives and priorities and which oversees registry activity and processes. The remit of the governance group should be clearly defined and should be publicly stated on the registry website. Membership of the group should also be made known publicly and should include representatives of all key stakeholders including: patients (via patient groups); clinicians (via professional bodies); healthcare institutions; manufacturers (via trade associations), payers and regulators (device and clinical practice). In all aspects of the registry’s work, access to information of a personally or commercially confidential nature should be on a limited basis as appropriate.

### Legal and Ethical Requirements for Data Collection and Handling

It is important that registries comply with national / regional legal requirements (e.g. HIPAA) for data collection and handling (data protection). Personal information about patients should be treated as confidential at all stages of registry activity and attention should be given to the control over transmission of any personal data (within the registry, linking to other data sources and to third parties), particularly on a cross-border basis. Using methods for concealing of personal information should be considered (where appropriate when sharing data) but the methods should not sacrifice longitudinal linkages of individual patient data. The registry should have a documented policy on data collection and handling, which should be agreed by the registry’s governance group. As new types of data uses are added, data handling policy should be updated and transparent to the public.

Commercial confidentiality should be maintained. Registries should ensure that they do not share data that would lead to misuse or provide a business advantage to one manufacturer over another.

### Policy on Conflict of Interest

Conflict of Interest (CoI) potentially influences the collection and analysis of registry data, as well as any decision-making based on such results. As the registry assessment tool is intended to qualify the registry that is utilized to support regulatory decision-making, it is critically important to understand the management of Conflict of Interest. The CoI of the Members of the Registry Steering Committee and Data Utilization Committee (when established) should be disclosed to the public through web-based technologies or other documents according to the predefined rules for understanding the management of CoI. The registry should have a policy on the management of CoI, which should be agreed to by the registry governance structure and which should be published on the registry’s website. When the data is utilized by stakeholders for assessing the performance of the device, and safety surveillance, members of the Committees or other registry related personnel such as statisticians, epidemiologists, data managers who have a conflict of interest must be excluded from the analysis team. When requested by the stakeholder including the regulatory authority, this information should be available especially if the data or results of analysis are used to support regulatory decision.

### Policy on Access to Data

The registry should develop a policy and establish procedures governing data access and use. Such policy should identify, for each relevant stakeholder (depending on intended use of the data) the appropriate level of data access. Data stored in the registry should be maintained in the data repository after the data cleaning is conducted. Any change of data must be recorded in the entry log. After cleaning, the data may be accessed by the stakeholders including manufacturer, regulatory authority as well as academic or professional societies upon request. Any request should be reviewed and approved by the Data Utilization Committee (when established) or by the Steering Committee which determines the appropriateness of the request for data access and use. Since data may include the patient level information and unique device identification information depending upon the nature of the assessment, confidentiality should be maintained. Registry data should be accessible to regulatory bodies in support of regulatory decision-making.

### Reports - Key Elements, Frequency and Web- reporting

It is important to enhance the objective of the registry reports especially with reference to the correlations with the vigilance (see the reference to the safety signals on implant deficiency). The reports published by the registries are recommended to include the number of devices used, overall percentage of patient exposure to the device that is captured in the registry, representativeness of the registry population to the treated population, patient demographic data (presented as aggregated data), procedure related information, major outcomes captured in the registry and via linkage, and methods used to generate results.

Publication of data should respect the national / international rules for data protection. The reports should contain the results of the preliminary and final assessment of the accumulated data including the adjusted analyses. The information regarding device-related adverse events should be reported in conjunction with the report to the manufacturer, physicians, and regulatory agencies. It is recommended that reports are published annually using agreed upon format. The methodology applied for the adjusted analyses should be available to regulators upon request.

Websites are important tools for informing all stakeholders concerning various aspects of a registry, their internal processes, and findings identified safety signals on implant deficiency or limitations of their evaluations. The registries should be encouraged to take proactive use of this opportunity. Annual Reports as well as scientific publications (e.g., peer reviewed publications or practice guidelines) use of the registry source for determining outcomes-based quality assessments, validated predictive risk modeling, signal detection, performance improvement, benchmarking, and other clinically-meaningful uses.

### Essential Information Available for Verification by Relevant Authority

Regulatory bodies should be able to verify essential information needed for their decision making. Registries contact information and processes to support data verification should be readily available. Any clinical data used for regulatory processes should be disclosed and can be subject to audit, if the information available in regulatory submission does not cover all relevant questions concerning validity and reliability.

### Information on Patient Data Protection and Data Security

The registry should have a documented policy on patient consent to be included in the registry, agreed by the registry governance body (steering committee / board) and published on the registry website. The policy should take into account relevant national / regional / international legal requirements including those related to exemption from the need to gain patient consent for data recording and approved by an Ethical Committee / IRB.

Where consent is required (opt-in / opt-out) the registry should have a specific consent form (or a standardized form of words to be included in the consent documentation for the clinical procedure) which should be published on the registry website along with a clearly worded explanation of the consent requirements and processes. See for example the consent forms plus associated explanatory leaflets for the UK National Joint Registry - <http://www.njrcentre.org.uk/njrcentre/Patients/IntroductiontotheNJR/NJRconsent/tabid/92/Default.aspx>. The form and explanatory information should be in plain language and it should be made available in relevant official languages of the country / region where the registry operates. The registry should take steps to ensure that all of those involved in the process of obtaining patient consent for their information to be included in the registry are aware of the consent requirements and the registry should monitor that they are fulfilling these requirements.

## Quality and Methodology Processes Leading to Actionable Data

### Relevant Variables and Use of Controlled Vocabularies

Registries are usually established for non-regulatory purposes (e.g. improvement of clinical care). Therefore, regulators should carefully assess whether the individual variables collected by the registry are sufficient in the number and scope to be used for regulatory purposes. For analysis and interpretation of registry generated data, it is important to have a common set of data elements, a common definitional framework (i.e., data dictionary), and pre-specified time intervals for data element collection and outcome analyses.

The recommended minimum set of variables (case report form or data collection tool) should satisfy regulatory purpose / decision making, clinical area of interest and study design employed to address particular questions. In general, the list of variables should include demographic factors, medical history / co-morbidities, procedure / device information, operators / physicians, follow-up information, and outcomes of interest.

The data elements available for analysis should be capable of addressing the specific question of interest to regulators when valid and appropriate analytical methods are applied. The distinction should be made between the elements that all registries would share and the specifics needed in each specialty areas. The role of specialty societies and organizations in countries will continue to be critical and need to be coordinated internationally as well as elements of all use (social and demographic elements). Modular add-on data (prospective trials) or links to data from other sources (retrospective data) when additional granular data not included in the standard registry dataset is needed for regulatory decision to be possible.

### Use of nationally/internationally harmonized data models

Registries should adhere to internationally / nationally recognized standards for harmonization of the CDM (Common Data Models). For example, in the United States several common data models are harmonized nationally (OMOP, Sentinel / PCORNet etc.). To advance medical device evaluation, Medical Device Epidemiology Network (MDEpiNet) pioneered international harmonization of disease specific-clinically relevant common data models. Specifically, MDEpiNet’s International Consortium of Orthopedic Registries (ICOR) data model for joint replacement was among the first, and International Consortium of Vascular Registries (ICVR) is currently being developed. This is particularly important in anticipation of evolving international convergence efforts (including reporting methodologies).

### Registry Data Management and Quality Management Programs

The data collection procedures used for registries should be clearly defined and described in a detailed data management standard operating procedures (SOP) manual. The records regarding the assessment of adherence to the registry’ s established data quality assurance and quality control policies and procedures, the quality of data element population (e.g., whether abstracted from a verifiable source to assess transcription errors or automatically populated through a data extraction algorithm). Summary information related to management and data quality check process should be publicly available describing how potential confounders due to incomplete documentation or data handling processes are managed.

To be used for regulatory purposes, registries should demonstrate to detect the following information:

* The overall percentage of patient exposure to the device that are captured in the registry and representativeness of the registry population to the treated population;
* The extent to which exposed patients within the scope of the registry are actually consecutively captured (i.e., minimization of selection bias);
* Extent of follow-up available at important durations of times following the index procedure; if inadequate, ability to link to additional datasets may potentially be a good surrogate;
* Qualifications of data entry personnel if direct data quality/validation is not possible;
* Adherence to source verification procedures and data collection and recording procedures for completeness and consistency;
* Completeness (i.e., minimized missing or out of range values) of data necessary for specified analyses, including variables required for adjustment/confounding factors;
* Data consistency across sites and over time;
* Evaluation of on-going training programs for data collection and use of data dictionaries at participating sites;
* Evaluation of site and data monitoring practices;

### 5. 4. 4. Conduct of Analyses across Different Types of Analysis Framework

Processes applied to registry data, such as analysis and risk adjustment modeling and inferences, can have a fundamental impact on conclusions drawn. A previous IMDRF Document “Methodological Principles in the Use of International Medical Device Registry Data” has outlined core methodological aspects Methodological Principles in the Use of International Medical Device Registry Data, IMDRF/Registry WG/N42FINAAL: 2017.

# APPENDIX 1: Proposed Assessment Check List by Regulatory Use

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **ELEMENTS** | **REGULATORY USE** | | | | | |
|  | Primary Approval | Broadening Indication | Post Market Study | Postmarket Surveillance | Development of  OPC/PG | Device Tracking and Field Safety Corrective Actions |
| **Device Identification** |  | | | | | |
| Unambiguous Device Identification (preferably internationally recognized UDI system) | needed | needed | needed | needed |  | needed |
| **Patient Identification** |  |  |  |  |  |  |
| Patient Identification | unique  needed | limited acceptable | limited acceptable |  |  | unique needed |
| **Linkability (Registry with other data source)** |  |  |  |  |  |  |
| Deterministic | XX | X | X |  |  |  |
| Probabilistic | (not recommended) | XX | XX | XX |  |  |
| **Transparency and Governance** |  |  |  |  |  |  |
| Governance structure and processes | XX | XX | XX | X | XX | X |
| Legal requirements for data collection/handling | XX | XX | XX | X | XX | X |
| Policy on COI | XX | XX | XX | XX | XX | XX |
| Policy on access to data | XX | XX | XX | XX | XX | XX |
| Report; Key elements and frequency of reports | X | X | X | X | X |  |
| Website and web-reporting | X | X | X | X | X | X |
| Essential information available for verification by relevant authority (e.g. competent authority, notified body) | XX | XX | XX | XX |  |  |
| Information on Patient Data Protection (e.g. if Exempt from consent, Opt-out, Opt-in) | XX | XX | XX |  | XX | XX |
| **Quality and Methodology Processes Leading to Actionable Data** |  |  |  |  |  |  |
| List of Relevant Variables and Use of Controlled Vocabularies | XX | XX | XX | XX | X | X |
| Use of nationally/internationally harmonized minimum data model | X | X | X | X | X |  |
| Registry Management processes (e.g. coverage, completeness, data quality control and assurance, etc.) | XX | XX | XX | XX | XX |  |
| Conduct of analyses across different types of analysis frameworks | NA | NA | NA | XX | XX |  |

|  |
| --- |
| **Legend**  *XX - Highly Recommended*  *X - Desirable*   * *Optional*   *NA - Not Applicable* |